|
gptkbp:instanceOf
|
immunosuppressant
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:affiliatedWith
|
immunosuppressant
macrolide lactone
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AD02
|
|
gptkbp:availableOn
|
capsule
injection
extended-release tablet
|
|
gptkbp:brand
|
gptkb:Prograf
gptkb:Advagraf
gptkb:Astagraf_XL
|
|
gptkbp:CASNumber
|
104987-11-3
|
|
gptkbp:chemicalFormula
|
C44H69NO12
|
|
gptkbp:contraindication
|
hypersensitivity to tacrolimus
|
|
gptkbp:developedBy
|
gptkb:Fujisawa_Pharmaceutical_Co.
|
|
gptkbp:discoveredIn
|
1984
|
|
gptkbp:eliminatedIn
|
bile
|
|
gptkbp:genericName
|
gptkb:tacrolimus
|
|
gptkbp:halfLife
|
12 hours (approximate)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prograf
|
|
gptkbp:interactsWith
|
gptkb:sirolimus
gptkb:milk
gptkb:cyclosporine
gptkb:phenytoin
gptkb:rifampin
gptkb:erythromycin
gptkb:ketoconazole
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Astellas_Pharma
|
|
gptkbp:mechanismOfAction
|
immunosuppressant
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
liver
|
|
gptkbp:origin
|
gptkb:Streptomyces_tsukubaensis
|
|
gptkbp:patentExpired
|
2008 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:sideEffect
|
hypertension
nephrotoxicity
neurotoxicity
hyperglycemia
increased risk of infection
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of organ transplant rejection
|
|
gptkbp:bfsParent
|
gptkb:Astellas_Pharma
|
|
gptkbp:bfsLayer
|
5
|